Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland; Department of Neurosurgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland.
World Neurosurg. 2022 Sep;165:e668-e679. doi: 10.1016/j.wneu.2022.06.122. Epub 2022 Jun 30.
Anterior communicating artery aneurysms (ACoAAs) are challenging to treat both surgically and endovascularly. In this study, we evaluate the treatment-related morbidity and clinical outcome of microsurgical clipping and endovascular treatment for a consecutive series of unruptured ACoAAs while the treatment paradigm was in transition from surgical to endovascular first.
We retrospectively reviewed clinical and radiologic data of adult patients who underwent microsurgical clipping or endovascular treatment of an unruptured ACoAA at a high-volume academic neurovascular center (Helsinki University Hospital) during 2012-2019. During this period, a transition from microsurgical clipping to endovascular treatment took place. Regarding outcome, we focused on treatment-related complications, discharge-to-home rates, functional performance (modified Rankin Scale score), and obliteration rates.
Of 128 treated ACoAAs, 81 (64%) were treated surgically and 47 (36%) endovascularly. There was no difference in major complications, intracranial hemorrhagic complications or ischemic complications, discharge-to-home rates, or functional performance between the surgically and endovascularly treated patients. With time, a decrease in major complications was observed in the surgical cases (from 29% to 17%), whereas the major complication rate increased in the endovascularly patients (from 0% to 25%). Cerebral ischemia was the most frequent complication in both groups. The risk for permanent neurologic deficit remained low in both groups (9% for endovascular and 5% for surgery).
We did not find any major differences regarding complications and outcomes after the treatment paradigm shift from clipping to endovascular of unruptured ACoAAs. Prospective studies evaluating durability of treatments are needed to compare overall effectiveness.
前交通动脉动脉瘤(ACoAA)在手术和血管内治疗方面都具有挑战性。本研究评估了在从手术优先向血管内优先的治疗模式转变过程中,对一系列未破裂的 ACoAA 连续病例进行显微夹闭和血管内治疗的相关治疗发病率和临床结局。
我们回顾性分析了 2012 年至 2019 年期间在高容量学术神经血管中心(赫尔辛基大学医院)接受未破裂 ACoAA 显微夹闭或血管内治疗的成人患者的临床和影像学数据。在此期间,治疗模式从显微夹闭向血管内治疗转变。关于结局,我们重点关注治疗相关并发症、出院回家率、功能表现(改良 Rankin 量表评分)和闭塞率。
在治疗的 128 个 ACoAA 中,81 个(64%)接受了手术治疗,47 个(36%)接受了血管内治疗。手术和血管内治疗患者之间在主要并发症、颅内出血性并发症或缺血性并发症、出院回家率或功能表现方面没有差异。随着时间的推移,手术病例的主要并发症发生率下降(从 29%降至 17%),而血管内治疗病例的主要并发症发生率增加(从 0%升至 25%)。在两组中,脑缺血都是最常见的并发症。两组永久性神经功能缺损的风险仍然较低(血管内治疗为 9%,手术治疗为 5%)。
在未破裂的 ACoAA 从夹闭到血管内治疗的治疗模式转变后,我们没有发现任何并发症和结局方面的重大差异。需要前瞻性研究来评估治疗的耐久性,以比较总体疗效。